Klisyri

Tirbanibulin, the active ingredient in Klisyri, is a kinase inhibitor presented as a 1% w/w topical gel for topical use. It is indicated for the treatment of actinic keratosis of the face and scalp in adult patients. The formulation is designed for once‑daily application to the affected skin areas, providing localized drug delivery with minimal systemic exposure.

GNH USA supplies Klisyri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance and regulatory compliance across all markets.

Klisyri (tirbanibulin) is a topical anti‑neoplastic agent used to treat actinic keratosis, a precancerous skin lesion. - Actinic keratosis of the face: reduces lesion count and prevents progression to squamous cell carcinoma. - Actinic keratosis of the scalp: clears lesions and improves skin appearance.

Klisyri may cause local skin reactions and, rarely, more severe adverse events.

Common Side Effects: - Erythema: redness at the application site. - Crusting or scaling: formation of dry, flaky skin. - Itching or burning sensation: mild to moderate discomfort. - Swelling or edema: localized puffiness.

Serious or Rare Side Effects: - Severe allergic reaction: signs include widespread rash, hives, or difficulty breathing. - Ulceration or infection of the treated area: persistent open sores or signs of bacterial infection.

Before using Klisyri, consider the following precautions: - Avoid application on compromised or inflamed skin: use only on intact lesions. - Do not apply to mucous membranes or ocular areas: risk of irritation. - Use as directed by a qualified prescriber: follow the prescribed treatment duration. - Monitor for excessive local reactions: discontinue and seek medical advice if severe. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Klisyri has limited systemic interactions, but topical co‑applications may affect safety or efficacy.

Major Interactions (Avoid): - Concurrent use with other topical anti‑neoplastic agents (e.g., 5‑fluorouracil, imiquimod): may increase irritation. - Application over areas treated with systemic kinase inhibitors: potential additive pharmacologic effect.

Moderate Interactions (Monitor Closely): - Use with photosensitizing drugs (e.g., tetracyclines): may enhance sun sensitivity. - Co‑application of potent topical corticosteroids: could reduce tirbanibulin efficacy. - Over‑the‑counter skin irritants (e.g., harsh exfoliants): may exacerbate local reactions.